Obeticholic Acid and Edaravone Protect Against Cisplatin‐Induced Hepatotoxicity Through Modulation of Keap1/Nrf2/ARE, TNF‐α/NF‐κB, and AKT/GSK‐3β Pathways
Journal of Biochemical and Molecular Toxicology · 2026
DOI: 10.1002/jbt.71101 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Biochemical and Molecular Toxicology, 2026. Verfasst von Fares E M Ali und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Toxicology, Faculty of Pharmacy, Al-Azhar University, Assiut, Egypt. Hauptthemen laut MEDLINE: Edaravone, NF-E2-Related Factor 2, Cisplatin, Glycogen Synthase Kinase 3 beta. Die Arbeit nennt 79 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Hepatotoxicity is one of the most crucial side effects of chemotherapy administration. Obeticholic acid (OCA) is a semisynthetic bile acid and farnesoid X receptor (FXR) agonist derived from chenodeoxycholic acid, with reported antioxidant and anti‐inflammatory effects in liver disorders. This study investigated the hepatoprotective effect of OCA against commonly used chemotherapy cisplatin (CP)‐induced hepatotoxicity in rats, as well as the modulatory effects of edaravone (EDA), a potent free radical scavenger, on its effects. Rats were divided into five groups: control (received vehicle), CP (7.5 mg/kg), EDA (30 mg/kg) + CP, OCA (30 mg/kg) + CP, and EDA + OCA + CP. The results of the present study demonstrated that both OCA and EDA significantly mitigated liver damage caused by CP, as evidenced by restoring liver enzymes and histological structure, reestablishment of oxidant/antioxidant status, suppression of inflammation, and attenuation of pro‐death signaling. The study highlights the role of key molecular pathways, including Keap1/Nrf2/HO‐1,HO‐1, TNF‐α/NF‐κB, and AKT/GSK‐3β, in the hepatoprotective mechanisms of OCA. Collectively, these findings suggest that OCA and EDA, particularly in combination, attenuate CP‐induced hepatotoxicity and are associated with coordinated modulation of oxidative stress, inflammatory signaling, and AKT/GSK‐3β‐associated pro‐survival/pro‐death pathways.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology and Toxicology, Faculty of Pharmacy, Al-Azhar University, Assiut, Egypt.
- Michael Sayegh, Faculty of Pharmacy, Aqaba University of Technology, Aqaba, Jordan.
- Department of Clinical Pharmacy, Al-Rayan National College of Health Sciences, Al-Rayan National College, Medina, Saudi Arabia.
- Department of Clinical Pharmacy, Faculty of Pharmacy, Al-Azhar University, Assiut, Egypt.
- Biochemistry and Molecular Biology Department, Faculty of Pharmacy (Girls), Al-Azhar University, Cairo, Egypt.
- Department of Pharmacology, Faculty of Medicine, Al-Azhar University, Assiut, Egypt.
ORCID-Profile: Fares E M Ali
Zitieren
APA
Ali, F. E. M., Bakr, A. G., Shalkami, A. S., El-Shoura, E. A. M., Ahmed, L. K., Abd-Elsalam, A. F., Ahmed, A. A. N., & Hassanein, E. H. M. (2026). Obeticholic Acid and Edaravone Protect Against Cisplatin‐Induced Hepatotoxicity Through Modulation of Keap1/Nrf2/ARE, TNF‐α/NF‐κB, and AKT/GSK‐3β Pathways. Journal of Biochemical and Molecular Toxicology. https://doi.org/10.1002/jbt.71101
Vancouver
Ali FEM, Bakr AG, Shalkami AS, El-Shoura EAM, Ahmed LK, Abd-Elsalam AF, et al. Obeticholic Acid and Edaravone Protect Against Cisplatin‐Induced Hepatotoxicity Through Modulation of Keap1/Nrf2/ARE, TNF‐α/NF‐κB, and AKT/GSK‐3β Pathways. Journal of Biochemical and Molecular Toxicology. 2026. doi:10.1002/jbt.71101
BibTeX
@article{Ali2026,
author = {Ali, Fares E M and Bakr, Adel G and Shalkami, Abdel-Gawad S and El-Shoura, Ehab A M and Ahmed, Lamiaa Khalaf and Abd-Elsalam, Ali F and Ahmed, Ahmed A N and Hassanein, Emad H M},
title = {Obeticholic Acid and Edaravone Protect Against Cisplatin‐Induced Hepatotoxicity Through Modulation of Keap1/Nrf2/ARE, TNF‐α/NF‐κB, and AKT/GSK‐3β Pathways},
journal = {Journal of Biochemical and Molecular Toxicology},
year = {2026},
doi = {10.1002/jbt.71101}
}
EUVIMED